- Home
- EYPT vs JBGS Comparison
EYPT vs JBGS Comparison
Compare EYPT & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | JBGS |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EYPT | JBGS |
|---|---|---|
| Price | $14.03 | $14.48 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $31.80 | $15.00 |
| AVG Volume (30 Days) | ★ 920.5K | 635.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.81% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $498,598,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $863.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $13.28 |
| 52 Week High | $19.11 | $24.30 |
Technical Indicators
Market Signals| Indicator | EYPT | JBGS |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 40.66 |
| Support Level | $11.74 | $14.12 |
| Resistance Level | $14.54 | $16.01 |
| Average True Range (ATR) | 0.72 | 0.48 |
| MACD | 0.21 | -0.00 |
| Stochastic Oscillator | 90.31 | 18.81 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.